115 completed. 115 Phase 3, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 115 | Completed 115 |
| Phase 2 | 21 | Completed 21 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia HSK39297 tablets - Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 3 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 36 | 2025-05-12 | 2026-02-11 |
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment HRS-5965 capsule - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 39 | 2025-01-07 | 2026-01-08 |
| A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy HRS-5965 capsule, Eculizumab Injection - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 76 | 2024-10-25 | 2025-09-11 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2024-10-10 | 2026-06-05 |
| Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia L-glutamine - Pulmonary Artery Pressure, Thalassemia | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 8 | 2023-08-15 | 2025-10-07 |
| Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China Eculizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 25 | 2023-07-05 | 2026-06-01 |
| Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. Iptacopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Novartis Pharmaceuticals | 52 | 2023-04-24 | 2026-01-13 |
| A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Pegcetacoplan, Placebo matching Pegcetacoplan - Cold Agglutinin Disease | Phase 3 | Completed | Swedish Orphan Biovitrum | 24 | 2022-10-20 | 2025-10-30 |
| L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity L-Arginine - Sickle Cell Disease | Phase 3 | Completed | Tanta University | 50 | 2022-07-25 | 2026-01-22 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan sutimlimab - Cold Agglutinin Disease | Phase 3 | Completed | Sanofi | 7 | 2021-11-11 | 2025-09-15 |
| Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) Spacing of Eculizumab infusions - Hemolytic-Uremic Syndrome, Atypical | Phase 3 | Completed | University Hospital, Tours | 40 | 2021-10-20 | 2025-03-25 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Iptacopan (LNP023) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Novartis Pharmaceuticals | 40 | 2021-07-19 | 2024-10-09 |
| Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial L-Arginine Hydrochloride, Normal saline - Sickle Cell Disease | Phase 3 | Completed | Claudia R. Morris | 271 | 2021-06-21 | 2026-06-23 |
| Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment LNP023, Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Novartis Pharmaceuticals | 97 | 2021-01-25 | 2024-10-09 |
| Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) Danicopan, Placebo, C5 Inhibitor - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 86 | 2020-12-16 | 2025-05-04 |
| Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients Hydroxyurea and Thalidomide - Thalassemia, Beta | Phase 2 / Phase 3 | Completed | Children's Hospital Karachi | 603 | 2020-07-07 | 2023-12-01 |
Showing 20 of 115. Sign in to see all of them.
Anemia, Sickle Cell (43) · Hemoglobinuria, Paroxysmal (29) · beta-Thalassemia (16) · Thalassemia (13) · Hematologic Diseases (10) · Anemia (8) · Iron Overload (7) · Vaso-Occlusive Crises (7) · Anemia, Hemolytic, Autoimmune (6) · Hemoglobinopathies (5) · Hemolysis (5) · Malaria (5) · Atypical Hemolytic Uremic Syndrome (4) · Myelodysplastic Syndromes (4)
Hemic and Lymphatic Diseases (115) · Anemia (107) · Hematologic Diseases (105) · Anemia, Hemolytic, Congenital (72) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (72) · Genetic Diseases, Inborn (70) · Hemoglobinopathies (63) · Bone Marrow Diseases (32) · Myelodysplastic Syndromes (27) · Pathological Conditions, Signs and Symptoms (16) · Thalassemia (13) · Metabolic Diseases (12) · Nutritional and Metabolic Diseases (12) · Pathologic Processes (11)
eculizumab (18) · Hydroxyurea (12) · ravulizumab (8) · Deferasirox (7) · Deferoxamine (5) · iptacopan (4) · Alemtuzumab (3) · Amlodipine (3) · Blood Transfusion (3) · Thalidomide (3) · sutimlimab (3) · Antibodies (2) · Arginine (2) · Artemether, Lumefantrine Drug Combination (2) · Certolizumab Pegol (2)
Alexion Pharmaceuticals, Inc. (12) · Novartis Pharmaceuticals (9) · National Heart, Lung, and Blood Institute (NHLBI) (6) · Assistance Publique - Hôpitaux de Paris (5) · Indiana University (3) · Mast Therapeutics, Inc. (3) · AO GENERIUM (2) · Agios Pharmaceuticals, Inc. (2) · Apellis Pharmaceuticals, Inc. (2) · Beni-Suef University (2) · Biocad (2) · Bioverativ, a Sanofi company (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · Children's Hospital Karachi (2) · Genetix Biotherapeutics Inc. (2)
United States (51) · France (32) · Italy (30) · United Kingdom (29) · Canada (22) · Germany (22) · Spain (19) · Netherlands (18) · Belgium (16) · South Korea (13) · Turkey (Türkiye) (13) · Australia (12) · Japan (12) · Brazil (11) · Egypt (10)
Michael R. DeBaun, MD, MPH (3) · Ahmed F Mahmoud Hussein, MS.c (2) · Claudia Morris, MD (2) · Donald Brambilla (2) · Alan Schwartz (1) · Ali Taher, Ass.Prof. (1)
PMID 37975597, PMID 17634466, PMID 19721013, PMID 30952488, PMID 31974203, PMID 33283989, PMID 33783815, PMID 34175041, PMID 34526067, PMID 36594181, PMID 38477987, PMID 38727860, PMID 38775255, PMID 39079163, PMID 40447351, PMID 40694294, PMID 40720060, PMID 16382063, PMID 16990386, PMID 17634458, PMID 17634459, PMID 17702897, PMID 17951527, PMID 18055865, PMID 18055982, PMID 18071721, PMID 18343277, PMID 18351337, PMID 18478575, PMID 19222413, PMID 19471252, PMID 19621454, PMID 19813252, PMID 19856395, PMID 19880138, PMID 19951979, PMID 19996412, PMID 20117244, PMID 20230403, PMID 20298497, PMID 20424435, PMID 20491747, PMID 20566896, PMID 20797449, PMID 20841509, PMID 21071497, PMID 21083671, PMID 21179892, PMID 21217080, PMID 21443536
2017 (5), 2016 (4), 2019 (2), 2004 (1), 2014 (1), K23HL136787 (1), N01HB07150 (1), N01HB07151 (1), N01HB07152 (1), N01HB07153 (1), N01HB07154 (1), N01HB07155 (1), N01HB07156 (1), N01HB07157 (1), N01HB07158 (1)